Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...

Sanofi has made an interesting choice for its new head of R&D, turning to Houman Ashrafian, who has deep expertise in the biopharma industry, but can also draw on his most recent role as managing ...

Please find enclosed communication for the attention of the shareholders of the Company for Apportionment of Cost of Acquisition of Equity Shares of Sanofi India Limited and Sanofi Consumer Healthcare ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,385.85 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...

The seller touts this diesel Land Rover as being “Noisy, leaky, rattly,” but says, “if you know what this is, you… ...

People keep coming back! This seller has many repeat buyers.